ivermectin - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID 19 hospitalized
	COVID-19 severe or critically
ivermectin	Galan Galan Camprubi Okumuş

15 studies excluded by filtering options 2

6080	IDEA, 2020	2	10	0	excluded	not a RCT	risk of bias not avaialble
6083	IFORS (Pott-Junior), 2020	2	1	3	excluded		high risk of bias
6096	Elgazzar - treatment, 2020	2	1	3	excluded		high risk of bias
6097	Elgazzar - prophylaxis, 2020	2	1	3	excluded		high risk of bias
6098	Patel, 2020	2	10	0	excluded	not a RCT	risk of bias not avaialble
6134	Morgenstern, 2020	2	30	0	excluded	not a RCT	risk of bias not avaialble
6368	Niaee (vs placebo), 2020	2	1	3	excluded		high risk of bias
6374	NCT04425850 (Caravallo), 2020	2	31	0	excluded	not a RCT	risk of bias not avaialble
6375	Cadegiani -Iver, 2020	2	99	0	excluded	not a RCT	risk of bias not avaialble
6379	Chamie-Quintero,, 2020	2	15	0	excluded	not a RCT	risk of bias not avaialble
6625	Nasir, 2020	2	31	0	excluded	not a RCT	risk of bias not avaialble
6625	Nasir, 2020	2	31	0	excluded	not a RCT	risk of bias not avaialble
7314	Samaha, 2021	2	1	3	excluded		high risk of bias
7995	Hazan, 2021	2	32	0	excluded	not a RCT	risk of bias not avaialble
10322	Elgazzar, 0	2	0	0	excluded		risk of bias not avaialble